1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Actinic Keratosis – Pipeline Review, H1 2013

Actinic Keratosis – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 60 pages

Actinic Keratosis – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Actinic Keratosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Actinic Keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Actinic Keratosis. Actinic Keratosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Actinic Keratosis.
- A review of the Actinic Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Actinic Keratosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Actinic Keratosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Actinic Keratosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Actinic Keratosis - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Actinic Keratosis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Actinic Keratosis 8
Actinic Keratosis Therapeutics under Development by Companies 10
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Actinic Keratosis Therapeutics - Products under Development by Companies 15
Companies Involved in Actinic Keratosis Therapeutics Development 16
Meda AB 16
NexMed, Inc. 17
Clinuvel Pharmaceuticals Limited 18
Quest PharmaTech Inc. 19
Digna Biotech, S.L. 20
Telormedix SA 21
GliaMed, Inc. 22
RIEMSER Arzneimittel AG 23
GENEXTRA S.p.A. 24
Advancell 25
Birken GmbH 26
Actinic Keratosis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
GM-1485 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
afamelanotide - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
TMX-202 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
sotirimod - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
OleogelS-10 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
fluorouracil - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
SL-017 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
ANs-40 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
OxBue/OxHex - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
ingenol mebutate - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
AK-3012 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
DAC-0060 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Actinic Keratosis Therapeutics - Drug Profile Updates 47
Actinic Keratosis Therapeutics - Discontinued Products 51
Actinic Keratosis Therapeutics - Dormant Products 52
Actinic Keratosis - Product Development Milestones 53
Featured News and Press Releases 53
Nov 19, 2012: LEO Pharma's Picato Gel Receives EU Marketing Authorization For Treatment Of Actinic Keratosis 53
Nov 05, 2012: Biofrontera Launches Ameluz In UK And Austria 54
Oct 15, 2012: Biofrontera And Bipharma Announce Launch Of Ameluz In Netherlands 54
Sep 20, 2012: Leo Pharma's Picato Obtains Positive Opinion From CHMP To Treat Actinic Keratosis In Adults 55
Sep 06, 2012: Moberg Derma Completes Recruitment For Phase II Study OF Limtop In Actinic Keratosis 55
Aug 27, 2012: Meda Announces Approval Of Zyclara In EU 56
Aug 13, 2012: Biofrontera Signs Distribution Agreement With Pelpharma For Marketing Of Ameluz In Austria 56
Jul 24, 2012: Biofrontera Signs Distribution Agreement With Spirit Healthcare For Marketing Ameluz In UK And Ireland 56
Jul 23, 2012: Biofrontera Discusses Approval Of Ameluz In US With FDA 57
Jun 21, 2012: CHMP Adopts Positive Opinion Recommending Granting Of Marketing Authorization For Zyclara 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables

Number of Products Under Development for Actinic Keratosis, H1 2013 8
Products under Development for Actinic Keratosis - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Meda AB, H1 2013 16
NexMed, Inc., H1 2013 17
Clinuvel Pharmaceuticals Limited, H1 2013 18
Quest PharmaTech Inc., H1 2013 19
Digna Biotech, S.L., H1 2013 20
Telormedix SA, H1 2013 21
GliaMed, Inc., H1 2013 22
RIEMSER Arzneimittel AG, H1 2013 23
GENEXTRA S.p.A., H1 2013 24
Advancell, H1 2013 25
Birken GmbH, H1 2013 26
Assessment by Monotherapy Products, H1 2013 27
Assessment by Stage and Route of Administration, H1 2013 29
Assessment by Stage and Molecule Type, H1 2013 31
Actinic Keratosis Therapeutics - Drug Profile Updates 47
Actinic Keratosis Therapeutics - Discontinued Products 51
Actinic Keratosis Therapeutics - Dormant Products 52

List of Figures

Number of Products under Development for Actinic Keratosis, H1 2013 8
Products under Development for Actinic Keratosis - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 27
Assessment by Route of Administration, H1 2013 28
Assessment by Stage and Route of Administration, H1 2013 29
Assessment by Molecule Type, H1 2013 30
Assessment by Stage and Molecule Type, H1 2013 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Acyl CoA Desaturase ...

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histamine H4 Recepto ...

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.